Look up one drug

Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Co Dorzotimolol · DIN 02404389 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2014-01-03 Health Canada: Cancelled post market since 2019-03-12 · brand ACT DORZOTIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Teva canada limited · schedule Prescription

DIN 02404389: Co Dorzotimolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id COB Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404389 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88915

Interchangeable products

Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951

Shortage status: not checked (no credentials)

Health Canada lists this DIN as Cancelled post market since 2019-03-12 — choose a marketed DIN from the same-category list.